|
To,
Sun Pharma Laboratories Limited
SUN House,
Mumbai.
Subject : A retrospective, cross-sectional observational survey study to analyze the role of Olanzapine in patients with acute exacerbation of schizophrenia.
In response to your letter, I agree to participate in the study as outlined by you.
I understand that:
-
You will provide me with a copy of the data collection plan and ________ DCFs.
-
All the data shared by me will be retrospective in nature.
-
The patient’s identity will not be disclosed in the DCF.
My personal details are given below for accuracy of your records.
*Mandatory to be filled
|